Beacon Therapeutics to evaluate Abeona’s AAV204 capsid for ophthalmology indications
July 12, 2024
Abeona Therapeutics Inc. and Beacon Therapeutics Ltd. have signed an agreement for evaluation by Beacon of Abeona’s patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.